sar425899 sanofi glp-1 glucagon dual agonist Focus on Glucagon-like Peptide- 1 Target: Drugs Approved or Designed to Treat Obesity Effects on weight loss and

In addition, the GLP-1 can inhibit postprandial gastric emptying and reduce gastric acid secretion, inhibit gastric and duodenal peristalsis by inhibiting vagus nerve, and increase the pressure of pylorus, thus reducing appetite, causing a reduction in body weight and participating in the so-called ileal braking effect (19, 35)

GLP-1 receptor agonists are medications that mimic this natural hormone

The widespread use of GLP-1 therapies, particularly in obesity, has raised questions about appropriate prescribing, long-term safety, and equitable access

The Phase 3 TRIUMPH program uses a similar step-up, targeting 6, 8, and 12 mg

Its to understand what your metabolic system actually needs, measure it, and then act